Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN069 in Chinese male participants with obesity or overweight
NCT06547775Phase 1Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KN-069 in obesity (5 arms), sponsored by Alphamab Oncology. Primary endpoint: Adverse Events at 42 days. Started Aug 2024; status: recruiting.
02
Drugs
KN-069
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06547775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547775.